

STEMLINE THERAPEUTICS, INC. (NASDAQ: STML)

Stemline 2Q13 Results a Non-Event. Reiterate Our BUY Rating and Increase Our Price Target to \$44 from \$36.

Investment Rating

BUY

| | |
|-------------------------|-------------------|
| Price Target | \$44.00 |
| Prior Price Target | \$36.00 |
| Price (August 16, 2013) | \$35.14 |
| 52 Week Range | \$10.33 - \$39.18 |
| Shares Outstanding | 12.4 MM |
| Market Capitalization | \$253 MM |
| Cash (June 30, 2013) | \$93 MM |

Fiscal Year End December

Revenue (MM's):

| | Current | Prior |
|-------|---------|-------|
| 2014E | \$0.0 | |
| 2013E | \$0.0 | |
| 2012A | \$0.0 | |

EPS GAAP:

| | Current | Prior |
|-------|----------|----------|
| 2014E | (\$2.37) | (\$2.40) |
| 2013E | (\$2.39) | (\$2.30) |
| 2012A | (\$1.82) | |

Quarterly EPS GAAP:

| | Current | Prior |
|---------|----------|----------|
| 2014E | | |
| Mar | (\$0.56) | (\$0.56) |
| Jun | (\$0.57) | (\$0.58) |
| Sep | (\$0.60) | (\$0.61) |
| Dec | (\$0.64) | (\$0.65) |
| 2013E | | |
| Mar (A) | (\$0.90) | |
| Jun (A) | (\$0.55) | (\$0.46) |
| Sep | (\$0.53) | (\$0.53) |
| Dec | (\$0.55) | (\$0.55) |

Highlights

STML 2Q13 results. STML reported EPS of (\$0.55) for 2Q13 (which was lower than our estimate of (\$0.46)). Operating expenses of \$5.2 million were \$0.6 million greater than our estimate of \$4.6 million (R&D expenses were \$4.1 million vs. our estimate of \$3.3 million and SG&A expenses were \$1.1 million vs. our estimate of \$1.3 million). As of June, 2013 STML had \$92.7 million in cash. We believe STML's current cash position is sufficient to generate significant SL-401 BPDCN and AML data and to reach into early 2016. We expect STML to have operating expenses between \$6 and \$7 million in 3Q13 and 4Q13.

SL-401 early clinical trial data have shown clear activity in the treatment of both AML and BPDCN. SL-401 with just a single cycle of therapy has shown a solid signal of tumor shrinkage in 5 out of 6 patients (83% ORR) with BPDCN, of which 3 (60%) of the responders were able to obtain a CR, one of which is durable for 9+ months (and is ongoing) and another for 5 months. Notably, there currently is nothing approved or thought to be meaningfully efficacious for the treatment of BPDCN, and the prognosis of BPDCN is dire with a median overall survival of 12 months. Therefore, we believe FDA approval via the BPDCN indication is potentially the most direct regulatory pathway for SL-401. Moreover, the FDA recently granted SL-401 Orphan drug status for the BPDCN indication. Additionally, we are impressed with SL-401's activity observed with only a single cycle of therapy and we look forward to additional data following multiple cycles of treatment which could enhance to the ORR and further extend the durability of the effects observed.

SL-401 and SL-701 clinical development update. Stemline plans to initiate a pivotal Phase 2b program with SL-401 for the BPDCN indication in 1H14 (we believe the BPDCN trial should take approximately 15 to 18 months to complete with pivotal data expected by 2H15. An NDA submission in 1H16 is expected, although an earlier submission date is also plausible if data are approval-worthy prior to full accrual, given that the trial is open-label) along with a pivotal Phase 2b trial for AML in 2H14. Additionally, Stemline anticipates initiating two Phase 2b trials for SL-701 in 2014 as well, to consist of one pediatric brainstem and non-brainstem glioma trial and one adult second-line GBM trial.

We believe STML's current value is primarily driven by SL-401. Our STML valuation and price target are primarily generated from our forecasted sales of SL-401. We believe Stemline's current valuation offers significant upside potential, particularly if the products are efficacious in the other indications Stemline plans to pursue, beyond BPDCN and AML. Specifically, we employed a sum-of-the-parts analysis based on the cash flow generated by SL-401. Our analysis employs only the U.S. revenue generated from SL-401 in relapsed and refractory AML and BPDCN patient populations, as well as the cash position at the projected price target date. We view STML, at current prices, as an attractive investment opportunity with significant upside potential.

We reiterate our BUY rating and increase our price target to \$44 from \$36. Our \$44.00 price target is based on a sum-of-the-parts (SOP) analysis employs the revenue generated from SL-401 in the relapsed and refractory AML, BPDCN and MDS patient populations, as well as the current cash position. The SOP analysis utilizes a 35% discount rate for SL-401 revenue from the U.S. and a 35% rate from the ex-U.S. royalties. The first line patients for AML and all royalty revenue for SL-701 represent upside potential.

Matthew L. Kaplan
212.891.5247
mkaplan@ladenburger.com

Disclosures and Analyst Certifications can be found in Appendix A.

NEW YORK, NY MELVILLE, NY MIAMI, FL BOCA RATON, FL NAPLES, FL HOUSTON, TX BOSTON, MA

520 Madison Avenue, New York, NY 10022 • Telephone: 212-308-9494

Member: NYSE, NYSE MKT, FINRA, all other principal exchanges and SIPC

Stemline's lead product SL-401: SL-401 is a targeted therapy directed to IL-3R present on tumor bulk and cancer stem cells (CSCs). SL-401 is a biologic recombinant protein comprised of human IL-3 fused to truncated diphtheria toxin (which inhibits protein synthesis). We believe SL-401 has the potential to be a best in class product for the treatment of BPDCN. The human IL-3 of SL-401 is able to target IL-3R, which is overexpressed on CSCs, which are responsible for re-population of the tumor and on leukemia blasts, which are responsible for the tumor bulk of AML, BPDCN, MDS, CML, ALL, Hodgkin's disease, multiple myeloma, and certain NHL's. Furthermore, SL-401 selectively targets cancer cells since IL-3R is only minimally expressed on non-cancer cells. Thus, we believe this explains why SL-401 is more tolerable and potentially has fewer adverse events and side effects (for example no evidence of hematologic toxicity) than the chemotherapies currently used to treat hematologic cancers.

Currently planned SL-401 Phase 2b trials:

AML registration-directed Phase 2b trial: A total of approximately 240 third-line AML patients are anticipated to be randomized 2:1 to either multiple cycles of SL-401 or physician's choice. Overall survival is the primary endpoint. We are anticipating this trial to be initiated in 2H14 with interim data in 2015-16. Enrollment could take approximately 1.5 years with final data expected by 2H16 (if the trial is not stopped earlier at an interim analysis), and an NDA filing in early- to mid- 2017 and potential market launch by late 2017/early 2018. Additionally, with interim analyses an earlier filing and approval is possible based on positive interim data, given the strong overall survival seen to date. We would anticipate such a trial to cost about \$25 - \$30 million in total and to fulfill both the U.S. and E.U. requirements.

Pivotal BPDCN Phase 2b trial: The pivotal single-arm BPDCN program, which will enroll up to approximately 40 to 50 patients in total with ORR (CR+PR) as the primary endpoint, is on track to start in 1H14. Given the orphan indication and the data from the previous 83 patient Phase 1/2 trial, we anticipate that this trial will satisfy the U.S. and E.U. requirements for marketing approval for the BPDCN indication. Due to the lack of therapeutic alternatives we anticipate a relatively rapid enrollment, which is more dependent on the incidence rate than patient choice. Thus we believe the trial should take approximately 15 to 18 months to complete with pivotal data expected by 2H15. An NDA submission in 1H16 is expected, although an earlier submission date is also plausible if data are approval-worthy prior to full accrual, given that the trial is open-label. Moreover, we believe that an accelerated FDA review is probable due to the stark unmet medical need in this patient population, which could enable approval by mid-2016, with a market launch in 2016 as well.

Phase 2b studies planned in other IL-3R over-expressing rare tumors: Stemline also plans to launch other SL-401 Phase 2 trials to examine the compound in other IL-3R over-expressing tumors including multiple myeloma, myelodysplastic syndrome (MDS) and certain rare disorders including hairy cell leukemia, mastocytosis, and basophilic leukemias. We expect these studies to start throughout 2014. We expect data from these open-label studies by end of 2014 and throughout 2015.

Future development: Future development may consist of combination trials of SL-401 with traditional chemotherapy for AML, earlier lines (i.e. second and first-line) of AML and the expansion into other indications such as MDS, multiple myeloma, CML, Hodgkin's, and NHLs. Development will also continue through independent investigator sponsored studies.

Impressive SL-401 Phase 1/2 data already presented. In a multi-center Phase 1/2 trial, patients with advanced hematologic malignancies were dosed with SL-401 using two different regimens to determine MTD. In regimen A, 45 patients were dosed with up to six intravenous (IV) infusions ranging from 4 to 12.5 µg/kg every other day, and in regimen B 35 patients were dosed with up to five IV infusions ranging from 7.1 to 22.1 µg/kg daily. Of the 83 patients enrolled 59 were relapsed or refractory AML patients, 11 were de-novo AML patients unfit for chemotherapy. Additionally, there were 7 patients with high-risk myelodysplastic syndrome (MDS), and 6 patients with relapsed or refractory BPDCN. The majority of the patients treated had greater than 3 prior lines of therapy.

The primary intent of the SL-401 Phase 1/2 trial was to determine the safety and tolerability of SL-401, but the trial also gave a clear efficacy signal. Given the intent to determine the maximum tolerable dose (MTD), this trial only dosed patients with one cycle of therapy, many of whom were dosed with below the therapeutically optimal doses of SL-401. Notwithstanding this fact, SL-401 was able to achieve responses of stable disease or tumor shrinkage in 46% of patients with relapsed or refractory AML and 83% of patients with relapsed or refractory BPDCN, which included 5 CRs, 2 in AML and 3 in BPDCN. Thus, with more than one cycle of treatment (which could convert patients who did not respond to responders, patients with SD to responders, patients with PRs to CRs, and/or responders to more durable responders) we hope to see an even greater response rate and an increase in the number of CRs and durable CRs achieved. We are impressed with the activity observed in this Phase 1/2 study. The overall survival (OS) of patients with third-line or greater AML receiving therapeutically relevant doses was improved to a median OS of 5.6 months (95% CI: 2.5, 10.8 months) versus the historical median OS of 1.5 months for patients with third-line AML treated with chemotherapy. This is promising as we anticipate a third-line AML pivotal trial to utilize OS as the primary endpoint.

Perhaps the most striking SL-401 efficacy data were shown in relapsed or refractory BPDCN patients, where 83% (5 out of 6) of patients responded, and 3 out of the 5 responders achieved CRs. One of the BPDCN CRs occurred in a third-line patient who had malignant blasts in the bone marrow and blood at baseline, all of which resolved after a single-cycle of SL-401 and lasted for 5 months. Another BPDCN CR occurred in a 4th line patient who, after a single-cycle of SL-401, has maintained a CR for 9 months and is currently ongoing. SL-401 has also been well tolerated, with no DLTs in the six BPDCN patients. Although these very early data are not yet statistically robust, the results are very encouraging given that lack of efficacy and the toxicity that BPDCN patients have experienced with existing therapies in the relapsed or refractory setting.

Table 1: Efficacy of single agent SL-401 with one cycle of therapy

| Efficacy measures | BPDCN (n=6) | AML Relapsed, refractory (n=59) | AML ≥3rd line (n=35) | AML Not chemo candidate (n=11) | MDS Refractory, High risk (n=7) |
|---------------------|----------------|---------------------------------------|----------------------------|--------------------------------------|---------------------------------------|
| Tumor shrinkages/SD | 83% | 46% | 43% | 55% | 43% |
| Tumor shrinkages | 83% | 25% | 23% | 27% | 29% |

Source: Company documents & Ladenburg Thalmann & Co.

Solid cash position. As of June 30, 2013 STML had \$93 million in cash. We believe STML's current cash position is sufficient to generate significant SL-401 BPDCN and AML data and to reach into early 2016.

Table 2: STML Sum-of-the-Parts Valuation

| Per share value of assets | | Weighted ave. product discount rate | 35.0% |
|---------------------------|----------|-------------------------------------|-------|
| SL-401 in the US | 33.06 | | |
| SL-401 in the EU | 3.64 | | |
| SL-701 in the US | - | | |
| SL-701 in the EU | - | | |
| Other | | | |
| Value of net cash | 7.20 | | |
| TP | \$ 43.90 | | |

Source: Ladenburg Thalmann & Co. Inc. Estimates

Valuation. Our \$44.00 price target is based on a sum-of-the-parts (SOP) analysis employs the revenue and generated from SL-401 in the relapsed and refractory AML, BPDCN and MDS patient populations, as well as the current cash position. The SOP analysis utilizes a 35% discount rate for SL-401 revenue from the U.S. and a 35% rate from the ex-U.S. royalties. The first line patients for AML and all royalty revenue for SL-701 are left as upside potential.

Table 3: Stemline Therapeutics – Upcoming Milestones

| Timing | Compound | Event | Indication |
|-----------|----------|---|------------|
| 1H14 | SL-401 | Initiate Pivotal program in BPDCN trial | BPDCN |
| mid-2014 | SL-401 | Initiate Phase 2 trial of other IL-3R+ indications | other |
| mid-2014 | SL-701 | Initiate Phase 2b adult second-line GBM trial | GBM |
| 2H14 | SL-701 | Initiate Phase 2b pediatric malignant glioma trial | GBM |
| 2H14 | SL-401 | Initiate Phase 2b of AML trial | AML |
| mid-15 | SL-401 | Phase 2b data | BPDCN |
| 2H15 | SL-401 | Interim Phase 2b data | AML |
| mid-2015 | SL-701 | Phase 2b data from adult second-line GBM trial | GBM |
| Late-2015 | SL-701 | Phase 2b data from pediatric malignant glioma trial | GBM |

Table 4: Stemline Therapeutics Pipeline

| | Preclinical | Phase I | Phase II | Pivotal | Approved |
|----------------------------------|-------------|---------|----------|---------|----------|
| SL-401: | | | | | |
| BPDCN | | | | | |
| Relapsed or refractory AML | | | | | |
| Other IL-3R ⁺ cancers | | | | | |
| SL-701: | | | | | |
| Pediatric glioma | | | | | |
| Adult high-grade glioma | | | | | |

Table 5: STML– Quarterly Financial Model

STEMLINE THERAPEUTICS Income Statement (December Fiscal Year; All amounts in '000s except per share items)

| | 2011A | 2012A | 1Q13A | 2Q13A | 3Q13E | 4Q13E | 2013E | 1Q14E | 2Q14E | 3Q14E | 4Q14E | 2014E | 2015E |
|--|----------------|----------------|----------------|----------------|----------------|----------------|-----------------|----------------|----------------|----------------|----------------|-----------------|-----------------|
| Sales/Royalties: | | | | | | | | | | | | | |
| SL-401 Revenue & Royalties | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SL-701 Royalties | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total product revenue and royalties | - | - | - | - | - | - | - | - | - | - | - | - | - |
| COGS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| R&D | 1,629 | 3,377 | 3,162 | 4,085 | 5,448 | 5,720 | 18,414 | 5,835 | 6,010 | 6,370 | 6,753 | 24,967 | 30,456 |
| G&A | 1,088 | 3,091 | 2,167 | 1,071 | 1,282 | 1,295 | 5,816 | 1,360 | 1,441 | 1,542 | 1,666 | 6,009 | 7,538 |
| Total operating expenses | 2,717 | 6,468 | 5,329 | 5,156 | 6,730 | 7,015 | 24,230 | 7,194 | 7,451 | 7,913 | 8,418 | 30,976 | 37,993 |
| Operating income (EBIT) | (2,717) | (6,468) | (5,329) | (5,156) | (6,730) | (7,015) | (24,230) | (7,194) | (7,451) | (7,913) | (8,418) | (30,976) | (37,993) |
| Other expenses | | | | | | | | | | | | | |
| Other income | 47 | 302 | 31 | - | 30 | 30 | 91 | 31 | 31 | 31 | 32 | 124 | 129 |
| Other expense | (10) | (0) | (125) | - | - | - | (125) | - | - | - | - | - | - |
| Interest expense | (99) | (119) | (82) | (298) | (99) | (100) | (580) | (100) | (101) | (101) | (102) | (405) | (413) |
| Interest income | 24 | 10 | - | 3 | 210 | 194 | 407 | 177 | 232 | 212 | 192 | 813 | 1,027 |
| Total other income (expense), net | (38) | 193 | (176) | (295) | 140 | 124 | (203) | 108 | 162 | 142 | 121 | 532 | 744 |
| Pretax Income | (2,755) | (6,275) | (5,506) | (5,451) | (6,590) | (6,891) | (24,433) | (7,087) | (7,289) | (7,770) | (8,297) | (30,444) | (37,250) |
| Benefit or (Provision for) income taxes | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | (2,755) | (6,275) | (5,506) | (5,451) | (6,590) | (6,891) | (24,433) | (7,087) | (7,289) | (7,770) | (8,297) | (30,444) | (37,250) |
| EPS basic | \$ (0.80) | \$ (1.82) | \$ (0.90) | \$ (0.55) | \$ (0.53) | \$ (0.55) | \$ (2.39) | \$ (0.56) | \$ (0.57) | \$ (0.60) | \$ (0.64) | \$ (2.37) | \$ (2.23) |
| EPS diluted, GAAP | \$ (0.80) | \$ (1.82) | \$ (0.90) | \$ (0.55) | \$ (0.53) | \$ (0.55) | \$ (2.39) | \$ (0.56) | \$ (0.57) | \$ (0.60) | \$ (0.64) | \$ (2.37) | \$ (2.23) |
| Basic shares outstanding | 3,442 | 3,442 | 6,148 | 9,837 | 12,359 | 12,583 | 10,232 | 12,696 | 12,810 | 12,926 | 13,042 | 12,868 | 16,716 |
| Diluted shares outstanding | 3,442 | 3,442 | 6,148 | 9,837 | 12,359 | 12,583 | 10,232 | 12,696 | 12,810 | 12,926 | 13,042 | 12,868 | 16,716 |

Source: Company documents and Ladenburg Thalmann & Co. estimates

APPENDIX A: IMPORTANT RESEARCH DISCLOSURES

ANALYST CERTIFICATION

I, Matt Kaplan, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report, provided, however, that:

The research analyst primarily responsible for the preparation of this research report has or will receive compensation based upon various factors, including the volume of trading at the firm in the subject security, as well as the firm's total revenues, a portion of which is generated by investment banking activities.

COMPANY BACKGROUND

Stemline Therapeutics is a biopharmaceutical company focused on the acquisition and development of oncology products that target cancer stem cells. STML's comparative advantage is to identify quality assets to develop. Lead product candidates are SL-401 and SL-701. SL-401 is indicated for AML, BPDCN and possibly other cancers that overexpress IL-3R. SL-701 is indicated for GBM, and is in line with the company's focus to target cancer stem cells. Stemline's management is a significant shareholder and strongly incentivized to achieve share price growth. Stemline operations are headquartered in New York, NY.

VALUATION METHODOLOGY

Our \$44.00 price target is based on a sum-of-the-parts (SOP) analysis employs the revenue and generated from SL-401 in the relapsed and refractory AML, BPDCN and MDS patient populations, as well as the current cash position. The SOP analysis utilizes a 35% discount rate for SL-401 revenue from the U.S. and a 35% rate from the ex-U.S. royalties.

RISKS

Revenue. There is no assurance that Stemline will be able to execute its development strategy, and generate the forecasted revenues. Moreover, there is no assurance that competitive products will not out compete Stemline's products, or that products not yet in existence or in the public space will be developed that may be superior to Stemline's products. Stemline is a development-stage biopharmaceutical company, and does not have any commercial products that generate revenues or any other sources of revenue. Stemline may never be able to successfully develop marketable products. Stemline's pharmaceutical development methods are unproven and may not lead to commercially viable products for any of several reasons. Stemline currently has no marketing and sales organization and no experience in marketing pharmaceutical products. If Stemline is unable to establish sales and marketing capabilities or fails to enter into agreements with third parties to market and sell any products it may develop, Stemline may not be able to effectively market and sell its products and generate product revenue. Stemline also faces product reimbursement risk. Thus, there is risk that our revenue forecasts are not met. Stemline has incurred net operating losses since its inception and we anticipate that they will continue to incur substantial operating losses for the foreseeable future. Stemline may never achieve or sustain profitability, which would depress the market price of its common stock, and could cause an investor to lose all or a part of their investment.

Commercial Partnerships. There is no assurance Stemline will be able to find a partner for products in its existing portfolio or if they are able to find a partner that the financial terms will be attractive to Stemline. Stemline focuses on in-licensing and developing products as its business strategy, and plans to continue to in-license products. There is no assurance that competitors will not be able to more effectively gain access to additional attractive product opportunities than Stemline. Stemline could face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than Stemline.

Regulatory. There can be no assurance that the FDA or other regulatory boards approve Stemline's current or future products. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if Stemline is ultimately unable to obtain regulatory approval for its product candidates, Stemline's business will be substantially harmed. Furthermore if Stemline initiates a clinical trial with SL-401 or other future product there can be no assurance these studies will be completed in a

timely manner, that results will support the intended regulatory or commercial purpose or that results will favorably impact either regulatory reviews or adoption by clinicians. Delays in the commencement of clinical trials and delays in the receipt of data from preclinical or clinical trials conducted by third parties could significantly impact Stemline's product development costs. Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials. Third parties have conducted all clinical trials of SL-401 and SL-701 so far, and Stemline's ability to influence the design and conduct of such trials has been limited. Stemline plans to assume control over the future clinical and regulatory development of such product candidates will entail additional expenses and require Stemline to rely on additional third parties. Any failure by a third party to meet its obligations with respect to the clinical and regulatory development of Stemline's product candidates may delay or impair their ability to obtain regulatory approval for their products.

Financing. The company's current financial resources should fund the company to 2H15. However, the commercial development of the company's products will require substantial direct funding from Stemline. There can be no assurance that revenue will materialize or adequately fund the company. Additionally, should Stemline require additional financial resources, there is no guarantee the company will have access to capital in the future on adequate terms, or at all.

Manufacturing. Stemline relies completely on third parties to manufacture preclinical and clinical pharmaceutical supplies and intends to rely on third parties to produce commercial supplies of any approved product candidate, and Stemline's commercialization of any of its product candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of the FDA, fail to provide Stemline with sufficient quantities of pharmaceutical product or fail to do so at acceptable quality levels or prices. Any quality control, manufacturing or stability concerns could negatively impact revenues.

Intellectual Property. Stemline's ability to generate revenue is dependent on market exclusivity of its products, such as SL-401 and SL-701. There is no guarantee that Stemline will be able to successfully defend its patents. Should Stemline's patents fail to provide market exclusivity, and should orphan drug designation also fail to provide market exclusivity, there is no assurance that the company will be able to generate revenue sufficient enough to fund operations. Changes in U.S. patent law could diminish the value of patents in general, thereby impairing Stemline's ability to protect their products.

For a full review of Stemline specific risk factors investors should refer to the Company's most recent forms 10K and 10Q on file with the SEC.

STOCK RATING DEFINITIONS

Buy: The stock's return is expected to exceed 12.5% over the next twelve months.

Neutral: The stock's return is expected to be plus or minus 12.5% over the next twelve months.

Sell: The stock's return is expected to be negative 12.5% or more over the next twelve months.

Investment Ratings are determined by the ranges described above at the time of initiation of coverage, a change in risk, or a change in target price. At other times, the expected returns may fall outside of these ranges because of price movement and/or volatility. Such interim deviations from specified ranges will be permitted but will become subject to review.

RATINGS DISPERSION AND BANKING RELATIONSHIPS (AS OF 7/31/13)

Buy: 76% (42% are banking clients)

Neutral: 24% (6% are banking clients)

Sell: 0% (0% are banking clients)

BIOTECHNOLOGY & HEALTHCARE SECTOR STOCKS UNDER AUTHOR ANALYST COVERAGE ("The Universe")

Antares Pharma (ATRS), Aradigm (ARDM), Bidel, Inc. (BIOD), BioDelivery Sciences International (BDSI), Cornerstone Therapeutics (CRTX), Dara Biosciences, Inc. (DARA), Flamel Technologies S.A. (FLML), Furiex Pharmaceuticals, Inc. (FURX), IsoRay (ISR), Keryx Biopharmaceuticals (KERX), MediciNova (MNOV), Nile

Therapeutics (NLTX), Prolor Biotech (PBTH), Repros Therapeutics (RPRX), Stemline Therapeutics (STML), TG Biosciences Inc. (TGTX), United Therapeutics (UTHR), and XOMA Corp. (XOMA).


COMPANY SPECIFIC DISCLOSURES

Ladenburg Thalmann & Co. Inc. makes a market in all of the stocks listed in The Universe with the exception of IsoRay (ISR), UnitedTherapeutics (UTHR) and Prolor Biotech, Inc. (PBTH). Among the companies in The Universe, Ladenburg Thalmann & Co. Inc. during the last 12 months had an investment banking relationship with Keryx Biopharmaceuticals (KERX), Aradigm (ARDM), Repros Therapeutics (RPRX), XOMA Ltd. (XOMA), Prolor Biotech (PBTH), Isoray Inc. (ISR), Antares Pharma (ATRS), Bidelivery Sciences Intl. (BDSI) and MediciNova(MNOV), Biodel Inc. (BIOD), TG Therapeutics Inc. (TGTX) and Dara Biosciences Inc. (DARA); Ladenburg Thalmann received compensation for investment banking services from Aradigm (ARDM), Repros Therapeutics (RPRX), Keryx Biopharmaceuticals (KERX), XOMA Ltd. (XOMA), Prolor Biotech (PBTH), Isoray Inc. (ISR), Antares Pharma (ATRS), and Bidelivery Sciences Intl (BDSI), Biodel Inc. (BIOD), TG Therapeutics Inc. (TGTX) and Dara Biosciences Inc. (DARA) in the last 12 months; Ladenburg Thalmann & Co. Inc. co-managed public offerings of securities for KERX, PBTH and ATRS, BIOD and TGTX in the past 12 months, acted as lead placement agent (Registered Direct Offering) and Lead Manager in secondary offerings for Repros Therapeutics (RPRX), acted as sole placement agent for a secondary offerings in Aradigm (ARDM), acted in an advisory capacity for Keryx Biopharmaceuticals (KERX), Aradigm (ARDM), Xoma Ltd. (XOMA), Repros Therapeutics (RPRX), Bidelivery Sciences Intl (BDSI) and MediciNova (MNOV), and acted as a placement agent for a registered direct offering in Isoray Inc. (ISR) and acted as a Lead Placement Agent for a registered direct offering in Dara Biosciences, Inc. (DARA) in the past 12 months; Ladenburg Thalmann & Co. Inc. expects to receive or intends to seek compensation for investment banking services during the next 3 months for all companies listed in The Universe. Among the companies listed in The Universe, the Analyst, or members of the Analyst's household, own (long position) securities issued by ARDM.

A member of an employee's household beneficially owns 1% or more of common equity securities of Dara Biosciences, Inc. (DARA). Dara Biosciences, Inc. also has a non - investment banking securities related services client relationship with Ladenburg Thalmann & Co. Inc. Antares Pharma (ATRS) and Teva Pharmaceuticals Industries (TEVA - Not Rated) have joint development interests in several injection devices.

Dr. Philip Frost serves as the Chairman of Teva and as Chairman of Ladenburg Thalmann Financial Services, the parent company of Ladenburg Thalmann & Co. Inc. Dr. Phillip Frost, Chairman of the Board of PBTH, beneficially owns 1% or more of common equity securities of PBTH. Members of the Board of Directors of the subject company have a noninvestment banking securities - related services client relationship with Ladenburg Thalmann & Co. Inc. A member of the Board of Directors of Stemline Therapeutics (STML) has an affiliation with Teva Pharmaceuticals Industries.

INVESTMENT RATING AND PRICE TARGET HISTORY



GENERAL DISCLAIMERS

Information and opinions presented in this report have been obtained or derived from sources believed by Ladenburg Thalmann & Co. Inc. to be reliable. The opinions, estimates and projections contained in this report are those of Ladenburg Thalmann as of the date of this report and are subject to change without notice.

Ladenburg Thalmann & Co. Inc. accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Ladenburg Thalmann & Co. Inc. This report is not to be relied upon in substitution for the exercise of independent judgment.

Ladenburg Thalmann & Co. Inc. may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and Ladenburg Thalmann & Co. Inc. is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

Some companies that Ladenburg Thalmann & Co. Inc. follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Ladenburg Thalmann & Co. Inc. research reports may not be suitable for some investors. Investors must make their own determination as to the appropriateness of an investment in any securities referred to herein, based on their specific investment objectives, financial status and risk tolerance.

Investing in low priced securities is speculative and carries a high degree of risk. You should independently investigate and understand all risks before making any investment. The markets for small cap stocks are highly speculative and this level of risk may not be appropriate for all investors. Some of the companies listed may be subject to the "Penny Stock Rule". Under this rule, the SEC has defined a "penny stock" to be any equity security which has a market price of less than \$5.00 share, subject to certain exemptions. Such exemptions include an equity listed security listed on NASDAQ and an equity security issued by an issuer which has (i) net tangible assets of at least \$2,000,000, if such issuer has been in continuous operational for three (3) years; (ii) net tangible assets of at least \$5,000,000, if such issuer has been in continuous operation for less than three (3) years; or (iii) average revenue of at least \$6,000,000 for the preceding three (3) years. Unless such exemption is available, regulations require delivery of a risk disclosure document explaining the penny stock market and the risks associated therewith prior to any transaction involving a penny stock. For stock not quoted on NASDAQ or at any time that the company has less than \$2,000,000 in net tangible assets, the trading in the common stock is covered under Rule 15c-9 under the Securities Exchange Act of 1934 for non-NASDAQ and non-exchange listed securities. Under such rule, broker-dealers who recommend covered securities to persons other than established customers and accredited investors must make a written suitability determination for the purchaser and receive the purchaser's written agreement to a transaction prior to sale. Some securities may not be cleared for sale in all states or other jurisdictions and LTCO assumes no responsibility to apprise you of individual states or jurisdictions' regulatory restrictions. Stocks in the microcap segment of market have risks that are not as common in other segments of market. These risks include, but are not limited to, liquidity risk, which can lead to higher volatility and low trade volume, company specific risks that contribute to lower valuation, higher probability of financial default and distress.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. The price, value of and income from any of the securities mentioned in this report can fall as well as rise. The value of securities is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities. Investors in securities such as ADRs, the values of which are influenced by currency volatility, effectively assume this risk. Securities recommended, offered or sold by Ladenburg Thalmann & Co. Inc. (1) are not insured by the Federal Deposit Insurance Company; (2) are not deposits or other obligations of any insured depository institution; and (3) are subject to investment risks, including the possible loss of some or all of principal invested. Indeed, in the case of some investments, the potential losses may exceed the amount of initial investment and, in such circumstances; you may be required to pay more money to support these losses.

The information and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy any securities mentioned herein. This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of Ladenburg Thalmann & Co. Inc.

Member: NYSE, NYSE MKT, FINRA, all other principal exchanges and SIPC

Additional Information Available Upon Request

© 2013 - Ladenburg Thalmann & Co. Inc. All Rights Reserved